Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132070) titled 'A prospective, multicenter, randomized controlled study on the combination regimen of reduced-dose versus standard-dose dexamethasone in the treatment of newly diagnosed multiple myeloma' on Sept. 9.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Qilu Hospital of Shandong University
Condition:
Multiple myeloma
Intervention:
Reduced-dose dexamethasone:Patients in this group adopt reduced-dose dexamethasone (20mg per week, 80mg per cycle).
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: 2025-07-11
Target Sample Size: Reduced-dose dexamethasone:110;Standar...